---
document_datetime: 2025-11-23 07:07:15
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/echogen.html
document_name: echogen.html
version: success
processing_time: 0.0421728
conversion_datetime: 2025-12-28 12:27:06.195118
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# EchoGen

[RSS](/en/individual-human-medicine.xml/65945)

##### Withdrawn

This medicine's authorisation has been withdrawn

dodecafluoropentane

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 17 July 1998, the European Commission issued a Marketing Authorisation valid throughout the European Union for the medicinal product EchoGen, which contains dodecafluoropentane. The pharmaceutical company responsible for this medicinal product is Sonus Pharmaceuticals Ltd.

On 8 November 2000, the Marketing Authorisation Holder notified the European Commission of its decision to withdraw the Marketing Authorisation for EchoGen.

On 22 January 2001, the European Commission adopted the decision withdrawing the Marketing Authorisation for EchoGen. Pursuant to this decision the European Public Assessment report for EchoGen has been removed from the EMA website.

It should be noted that the product had never been marketed within the European Economic Area.

## Product information

22/01/2001

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

## Product details

Name of medicine EchoGen Active substance dodecafluoropentane International non-proprietary name (INN) or common name dodecafluoropentane Therapeutic area (MeSH) Echocardiography Anatomical therapeutic chemical (ATC) code V08DA

### Pharmacotherapeutic group

Contrast media

### Therapeutic indication

EchoGen is a transpulmonary echocardiographic contrast agent for use in patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers, enhance left ventricular border delineation with resulting improvement in wall motion visualisation.

EchoGen should only be used in patients where the study without contrast enhancement is inconclusive.

## Authorisation details

EMA product number EMEA/H/C/000149 Marketing authorisation holder

Sonus Pharmaceuticals Ltd.

Knyvett House

Marketing authorisation issued 17/07/1998 Withdrawal of marketing authorisation 22/01/2001

**This page was last updated on** 22/05/2001

## Share this page

[Back to top](#main-content)